



INFORMATION SHEET

AMS Guide to MHT/HRT Doses New Zealand Only

This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different MHT/HRT products available in New Zealand in June 2024. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to help physicians change their patients to higher or lower approximate doses of MHT if needing to tailor therapy, or remain within the same approximate dose if needing to change brands of MHT. Private/non Pharmac subsidised script products are marked with an *.

Progestogen

Suggested alternative doses for use with the oestrogen preparations above where fixed dose therapy is not suitable

Low dose for use with low dose oestrogen		
Product	Presentation	Composition
Provera (1/2 of 5mg tablet)	tablet	2.5mg medroxyprogesterone acetate
Provera 2.5mg tablet*	tablet	2.5mg medroxyprogesterone acetate
Primolut N (1/4 of 5mg tablet)	tablet	1.25 mg norethisterone
Utrogestan*	capsule	100mg micronised progesterone orally for 25 days out of a 28-day cycle ¹ or 200mg orally daily for 12 days out of a 28-day cycle
Mirena* (Pharmac indication for menorrhagia/anaemia)	device (5 years)	20mcg/24hrs levonorgestrel

Medium dose for use with medium dose oestrogen ²		
Product	Present ⁿ	Dose
Primolut N (¼ of 5mg tablet)	tablet	1.25 mg norethisterone
Provera	tablet	5mg medroxyprogesterone acetate
Utrogestan*	capsule	100mg micronized progesterone orally 25 days out of a 28-day cycle ¹ or 200mg daily for 12 days of a 28-day cycle
Mirena* (Pharmac indication for menorrhagia/anaemia)	device (5 years)	20mcg/24hrs levonorgestrel

Higher dose (for use in cyclical therapy or continuous therapy with high dose oestrogen) ³		
Primolut N (1/2 5mg tablet)	tablet	2.5mg norethisterone
Provera	tablet	10mg medroxyprogesterone acetate
Mirena* (Pharmac indication for menorrhagia/anaemia)	device (5 years)	20mcg/24hrs levonorgestrel

1. Can be used daily if compliance is an issue.
2. Safe continuous or cyclic dose of micronised progesterone for use with oestradiol 2mg tablets is unknown due to insufficient data.
3. Safe continuous or cyclic dose of micronised progesterone for use with high dose oestrogen (75mcg patch or higher, or high dose oestrogen gels) is unknown due to insufficient data.

Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected material. Reproduction of this Information Sheet by Australasian Menopause Society Members and other health professionals for clinical practice is permissible. Any other use of this information (hardcopy and electronic versions) must be agreed to and approved by the Australasian Menopause Society. ID:2024-06-04

Oestrogen only therapy: Only use these if patient has had a hysterectomy or in combination with a progestogen or Mirena if intact uterus

Low dose		
Product	Presentation	Composition
Estrofem*	tablet	1mg 17 B oestradiol
Progynova	tablet	1mg oestradiol valerate
Premarin*	tablet	0.3mg conjugated equine oestrogen
Estradot 25#	transdermal patch	25 /24hrs 17B oestradiol (twice weekly application)
Estrogestin [^]	gel	0.75mg oestradiol = 1 pump
Medium dose		
Progynova	tablet	2mg oestradiol valerate
Estradot 50#	transdermal patch	50mcg/24 hours 17B oestradiol (twice weekly application)
Premarin*	tablet	0.625mg conjugated equine oestrogens
Sandrena**	gel	1mg oestradiol (daily application)
Estrogestin [^]	gel	1.5mg oestradiol = 2 pumps
High dose		
Estradot 75#	transdermal patch	75 or 100mcg/24 hours (twice weekly application)
Estradot 100#	transdermal patch	75 or 100mcg/24 hours (twice weekly application)
Estrogestin [^]	gel	2.25mg oestradiol = 3 pumps or 3.0mg oestradiol = 4 pumps
Oestradiol implants - No longer available		
Oestrogen only vaginal therapy		
If prescribing vaginal oestrogen rather than systemic hormone therapy, a progestogen is not required.		
Product	Presentation	Composition
Ovestin	cream	1mg/g oestriol
Ovestin	pessary	0.5mg oestriol

Note Sandrena is only available under Section 29 at online pharmacies.

[^]Note Estrogestin is only available under Section 29 direct from supplier Pharmaco.

#Note there is currently a shortage of Estradot so please prescribe Oestradiol patches to allow for substitutes to be dispensed.

Cyclical oestrogen and progestogen combination MHT

Use cyclical oestrogen and progestogen combinations at peri-menopause or if less than 12 months amenorrhoea

Medium dose		
Trisequens*	tablet	1 and 2mg oestradiol hemihydrate/1mg norethisterone acetate

Continuous oestrogen and progestogen combinations

Should be used if 12 months since LMP or after 12 months cyclical MHT

Low dose		
Product	Presentation	Composition
Kliovance*	tablet	1mg oestradiol hemihydrate/0.5mg norethisterone acetate
Other Low dose hormonal options		
Livial*, Xyvion*	tablet	2.5mg tibolone
Duavive* (oestrogen/SERM combination)	tablet	0.45mg conjugated equine oestrogens / 20mg bazedoxifene
Medium dose		
Kliogest*	tablet	2mg oestradiol/1mg norethisterone

Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected material. Reproduction of this Information Sheet by Australasian Menopause Society Members and other health professionals for clinical practice is permissible. Any other use of this information (hardcopy and electronic versions) must be agreed to and approved by the Australasian Menopause Society. ID:2024-06-04